CompletedNot Applicable

Safety of Etoricoxib (MK-0663) in Patients With Spondyloarthropathy (SpA)/Ankylosing Spondylitis (AS) in Sweden (EP07013.013.11.082)

21,108 participantsStarted 2011-02-15

Plain-language summary

The study is intended to provide additional post-marketing safety data regarding the use of etoricoxib for the indication of ankylosing spondylitis.

Who can participate

Age range16 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participant attended an out-patient clinic 2001-2010. * Participant is registered with an International Classification of diseases (ICD, Version 10)-code corresponding to SpA/AS and AS. Exclusion Criteria: Not applicable.

What they're measuring

Number of patients with Characteristics of inflammatory SPA/AS

Timeframe: Over a 12 year period (2001-2013)

Number of patients who used etoricoxib

Timeframe: Up to 7 1/2 years (Q3 2005 - 2013)

Number of patients who used other COX-2 inhibitors

Timeframe: Up to 7 1/2 years (Q3 2005 - 2013)

Number of patients who used nsNSAIDs

Timeframe: Up to 7 1/2 years (Q3 2005 - 2013)

Number of clinical outcomes of special interest

Timeframe: Up to 7 1/2 years (Q3 2005 - 2013)

Trial details

NCT IDNCT01327638

SponsorOrganon and Co

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2018-09-24

View on ClinicalTrials.gov More Spondylarthropathies; Spondylitis, Ankylosing trials